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OBJECTIVES 
The aim of this study was to find out how can the use of multiple criteria in Health technology assessment 
(HTA) influence outcome in different drug categories. Especially in relationship to orphan medicinal products. 
Next objective was to explore, which criteria are the most important in the value of the drug and to measure 
the difference in the preferences among three stakeholder groups in the Czech Republic.  
METHODS 
The set of 10 criteria was selected by the expert panel and 3 model treatments were described. Two-round 
questionnaire was developed and distributed among highly qualified representatives of three stakeholder 
groups (patients or carers, clinicians and policy makers). In the first round participants provided weights for 
each criterion by answering on the scale from 1 to 7. In second round participants scored model treatments 
according to their performance in each criterion. Normalized weights were combined with scores and 
treatments were ranked based on the overall value. Differences between stakeholder`s preferences were 
observed. The Kruskal-Wallis test (two-tailed) was used to assess statistical differences among stakeholder 
groups. 
Rankings of model treatments were compared to the one resulted from using the limited set of criteria. The 
change in the value of the orphan treatment based on the choice for the set of criteria for assessment was 
observed. Basic descriptive statistic methods were used (arithmetic mean, median, maximum and minimum 
value). 
RESULTS 
The study was completed by 27 (first round) and 13 participants (second round). Clinical effectiveness and 
quality of life were the most important criteria in all groups (relative weight  11.5%). Policymakers gave 
markedly higher weight to cost-effectiveness and budget-impact. All three stakeholder groups agreed on 
these criteria: length of life, quality of life, unmet need and safety (p>0.31). There was disagreement in other 
six criteria (p<0.03). In multi-criteria assessment orphan drug showed the highest value of model treatments, 
but when using the limited set of criteria (only cost-effectiveness and budget-impact) it showed the opposite 
– the lowest value out of studied model treatments.  
CONCLUSION 
Multiple-criteria assessment can add a value to HTA in cases where standard cost-effectiveness analysis is 
not possible to construct or is not a key to appraise an entire value (e.g. in orphan drugs). Some classes of 
drugs can be fundamentally affected by non-complexity of criteria used for the assessment. Overall higher 
societal value of these drugs may not be fully appreciated via standard Czech reimbursement process. 
Preferences varied markedly among stakeholders and therefore all should be ideally taken into account. 
